• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病增加了酒精性肝硬化等待肝移植患者发生肝细胞癌的风险。

Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants.

机构信息

Service d'Hépatogastroentérologie, Hôpital Pitié Salpêtrière, Paris, France.

Service de Chirurgie Hépatobiliaire et de Transplantation, Hôpital Pitié Salpêtrière, Paris, France.

出版信息

Clin Gastroenterol Hepatol. 2015 May;13(5):992-9.e2. doi: 10.1016/j.cgh.2014.10.011. Epub 2014 Oct 20.

DOI:10.1016/j.cgh.2014.10.011
PMID:25459558
Abstract

BACKGROUND & AIMS: Many patients with alcohol-associated cirrhosis also have diabetes, obesity, or insulin resistance-mediated steatosis, but little is known about how these disorders affect the severity of liver disease. We analyzed the prevalence and prognostic implications of metabolic risk factors (MRFs) such as overweight, diabetes, dyslipidemia, and hypertension in patients with alcohol-associated cirrhosis awaiting liver transplants.

METHODS

We performed a retrospective study of 110 patients with alcohol-associated cirrhosis (77% male; mean age, 55 y; 71% with >6 mo of abstinence) who received liver transplants at a single center in Paris, France, from 2000 through 2013. We collected data on previous exposure to MRFs, steatosis (>10% in the explant), and histologically confirmed hepatocellular carcinoma (HCC).

RESULTS

HCC was detected in explants from 29 patients (26%). Steatosis was detected in explants from 47 patients (70% were abstinent for ≥6 mo); 50% had a history of overweight or type 2 diabetes. Fifty-two patients (47%) had a history of MRFs and therefore were at risk for nonalcoholic fatty liver disease. A higher proportion of patients with MRF had HCC than those without MRF (46% vs 9%; P < .001). A previous history of overweight or type 2 diabetes significantly increased the risk for HCC (odds ratio, 6.23; 95% confidence interval [CI], 2.47-15.76, and odds ratio, 4.63; 95% CI, 1.87-11.47, respectively; P < .001). MRF, but not steatosis, was associated with the development of HCC (odds ratio, 11.76; 95% CI, 2.60-53; P = .001) independent of age, sex, amount of alcohol intake, or severity of liver disease.

CONCLUSIONS

Patients with alcohol-associated cirrhosis who received transplants frequently also had nonalcoholic fatty liver disease. MRFs, particularly overweight, obesity, and type 2 diabetes, significantly increase the risk of HCC.

摘要

背景与目的

许多患有酒精性肝硬化的患者还同时患有糖尿病、肥胖症或胰岛素抵抗性脂肪变性,但人们对于这些疾病如何影响肝脏疾病的严重程度知之甚少。我们分析了代谢危险因素(如超重、糖尿病、血脂异常和高血压)在等待肝移植的酒精性肝硬化患者中的流行程度及其预后意义。

方法

我们对 2000 年至 2013 年在法国巴黎的一家中心接受肝移植的 110 例酒精性肝硬化患者(77%为男性;平均年龄 55 岁;71%有≥6 个月的戒酒史)进行了回顾性研究。我们收集了有关以前暴露于代谢危险因素、脂肪变性(>10%在肝移植组织中)和组织学证实的肝细胞癌(HCC)的数据。

结果

在 29 例患者(26%)的肝移植组织中检测到 HCC。在 47 例患者(50%有≥6 个月的戒酒史)的肝移植组织中检测到脂肪变性;50%有超重或 2 型糖尿病病史。52 例(47%)有代谢危险因素史,因此有患非酒精性脂肪性肝病的风险。有代谢危险因素史的患者 HCC 比例高于无代谢危险因素史的患者(46%比 9%;P<.001)。超重或 2 型糖尿病的既往病史显著增加 HCC 的风险(比值比,6.23;95%置信区间[CI],2.47-15.76,和比值比,4.63;95%CI,1.87-11.47,分别;P<.001)。代谢危险因素(但不是脂肪变性)与 HCC 的发展相关(比值比,11.76;95%CI,2.60-53;P=.001),独立于年龄、性别、饮酒量或肝脏疾病严重程度。

结论

接受肝移植的酒精性肝硬化患者常同时患有非酒精性脂肪性肝病。代谢危险因素,尤其是超重、肥胖和 2 型糖尿病,显著增加 HCC 的风险。

相似文献

1
Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants.非酒精性脂肪性肝病增加了酒精性肝硬化等待肝移植患者发生肝细胞癌的风险。
Clin Gastroenterol Hepatol. 2015 May;13(5):992-9.e2. doi: 10.1016/j.cgh.2014.10.011. Epub 2014 Oct 20.
2
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.非酒精性脂肪性肝病、代谢风险因素与肝细胞癌:一个悬而未决的问题。
World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.
3
Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.酒精性或病毒性丙型肝硬化患者肝细胞癌的危险因素。
Clin Gastroenterol Hepatol. 2006 Aug;4(8):1062-8. doi: 10.1016/j.cgh.2006.05.013. Epub 2006 Jul 14.
4
Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B.合并脂肪肝会增加慢性乙型肝炎患者患肝细胞癌的风险。
J Gastroenterol Hepatol. 2017 Mar;32(3):667-676. doi: 10.1111/jgh.13536.
5
Hepatocellular carcinoma in nonalcoholic fatty liver cirrhosis and alcoholic cirrhosis: risk factor analysis in liver transplant recipients.非酒精性脂肪性肝硬化和酒精性肝硬化中的肝细胞癌:肝移植受者的危险因素分析。
Eur J Gastroenterol Hepatol. 2012 Jul;24(7):840-8. doi: 10.1097/MEG.0b013e3283534b40.
6
Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.肝脂肪变性与丙型肝炎相关肝硬化患者肝细胞癌发生频率增加有关。
Cancer. 2007 Jun 15;109(12):2490-6. doi: 10.1002/cncr.22701.
7
Association of nonalcoholic fatty liver disease and liver cancer.非酒精性脂肪性肝病与肝癌的关联
World J Gastroenterol. 2015 Jan 21;21(3):913-8. doi: 10.3748/wjg.v21.i3.913.
8
Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C.酒精性肝硬化且既往感染过丙型肝炎患者的肝细胞癌患病率
Am J Gastroenterol. 1993 Jan;88(1):39-43.
9
Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.非肝硬化非酒精性脂肪性肝病和代谢综合征背景下的肝细胞癌:美国的经验
Dig Dis Sci. 2015 Oct;60(10):3142-8. doi: 10.1007/s10620-015-3821-7. Epub 2015 Aug 7.
10
Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease.美国退伍军人中无肝硬化的肝细胞癌与非酒精性脂肪性肝病相关。
Clin Gastroenterol Hepatol. 2016 Jan;14(1):124-31.e1. doi: 10.1016/j.cgh.2015.07.019. Epub 2015 Jul 18.

引用本文的文献

1
Impact of high body mass index on hepatocellular carcinoma risk in chronic liver disease: A population-based prospective cohort study.高体重指数对慢性肝病患者肝细胞癌风险的影响:一项基于人群的前瞻性队列研究。
PLoS One. 2025 Jan 22;20(1):e0316175. doi: 10.1371/journal.pone.0316175. eCollection 2025.
2
Construction and validation of a SEER-based prognostic nomogram for young and middle-aged males patients with hepatocellular carcinoma.基于 SEER 数据库构建并验证用于预测青年和中年男性肝细胞癌患者预后的列线图
J Cancer Res Clin Oncol. 2023 Sep;149(12):10099-10108. doi: 10.1007/s00432-023-04901-0. Epub 2023 Jun 2.
3
Non-alcoholic fatty liver disease: Definition and subtypes.
非酒精性脂肪性肝病:定义和亚型。
Clin Mol Hepatol. 2023 Feb;29(suppl):S5-S16. doi: 10.3350/cmh.2022.0424. Epub 2022 Dec 28.
4
Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases.糖尿病、肥胖症和血脂异常对慢性肝病患者肝细胞癌风险的影响。
Clin Mol Hepatol. 2022 Oct;28(4):773-789. doi: 10.3350/cmh.2021.0383. Epub 2022 Aug 8.
5
Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study.非乙型肝炎病毒和非丙型肝炎病毒相关性肝细胞癌发病率的增加:单机构 20 年研究。
BMC Gastroenterol. 2021 Jul 31;21(1):306. doi: 10.1186/s12876-021-01884-5.
6
Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives.非酒精性脂肪性肝炎/非酒精性脂肪肝病的靶向治疗:从分子层面到药物及手术治疗选择
J Pers Med. 2021 Jun 2;11(6):499. doi: 10.3390/jpm11060499.
7
Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.系统评价与荟萃分析:非酒精性脂肪性肝炎且无肝硬化与其他肝病相比发生肝细胞癌的风险。
Aliment Pharmacol Ther. 2018 Oct;48(7):696-703. doi: 10.1111/apt.14937. Epub 2018 Aug 22.
8
NAFLD and liver transplantation: Current burden and expected challenges.非酒精性脂肪性肝病与肝移植:当前负担及预期挑战
J Hepatol. 2016 Dec;65(6):1245-1257. doi: 10.1016/j.jhep.2016.07.033. Epub 2016 Jul 30.